I need to do a topic presentation in dyslipidemia given me from AHA 2026 guidelines and ESC 2025
Asking for Preferences
Searching the Web
AHA 2026 dyslipidemia cholesterol guidelines key recommendations
Searching the Web
ESC 2025 dyslipidemia guidelines key recommendations LDL targets
Finding Sources
Reading File
Reading File
Reading Web Page
LDL targets treatment goals PCSK9 risk categories recommendations
Finding Sources
Running Command
Writing File
Running Command
Running Command
Your presentation is ready! Here is the download link:
Dyslipidemia AHA2026 ESC2025
Presentation · PPTX
What's Inside (20 Slides)
| # | Slide | Content |
|---|---|---|
| 1 | Title | Bold dark-navy design with AHA 2026 / ESC 2025 branding |
| 2 | Overview / Agenda | 10-item numbered roadmap |
| 3 | What is Dyslipidemia? | Definition, 4 types (LDL, HDL, TG, Lp(a)), epidemiology |
| 4 | Pathophysiology | Atherogenesis flow: LDL → oxidation → foam cells → plaque |
| 5 | Risk Assessment | PREVENT-ASCVD (AHA 2026) vs SCORE2/SCORE2-OP (ESC 2025) |
| 6 | Screening & Diagnosis | Lipid panel, universal Lp(a), ApoB — new 2025/2026 updates |
| 7 | AHA 2026 Key Changes | 6 major updates including PREVENT, restored goals, 5 new drugs |
| 8 | AHA 2026 LDL-C Goals | Goals by risk + full CAC scoring table |
| 9 | ESC 2025 Key Changes | Extreme risk, fire-to-target, bempedoic acid, special pops |
| 10 | ESC 2025 LDL-C Goals | 5-tier color-coded risk pyramid (<116 → <40 mg/dL) |
| 11 | Lifestyle Modifications | Diet, exercise, weight loss, smoking — foundation of all therapy |
| 12 | Pharmacotherapy | 6 drug classes with MOA, agents, LDL-C reduction %, guideline class |
| 13 | Treatment Algorithm | 5-step visual: lifestyle → statin → ezetimibe → PCSK9i → alternatives |
| 14 | Special Populations | Diabetes, FH, elderly, HIV/cardio-oncology |
| 15 | AHA vs ESC Comparison | 12-row side-by-side table — the "heart" of the presentation |
| 16 | Hypertriglyceridemia | Classification, causes, fibrates, REDUCE-IT (EPA) |
| 17 | Lp(a): The Emerging Biomarker | Both guidelines side-by-side; pelacarsen pipeline drug |
| 18 | Monitoring & Statin Safety | Timeline + 4 safety concerns (myopathy, diabetes, LFTs, cognition) |
| 19 | Take-Home Messages | 10 numbered key points |
| 20 | References & Thank You | 6 key citations (Blumenthal 2026, Mach 2025, CLEAR, REDUCE-IT, ORION) |
Design: Navy-dominant with crimson (AHA) and gold (ESC) accents, structured cards/boxes on every slide — no plain bullet walls. Calibri font throughout for professional medical conference look.
Give me in chat
Here is the full presentation content in chat:
🫀 DYSLIPIDEMIA
Management & Treatment Guidelines
AHA / ACC 2026 · ESC / EAS 2025
Focused Update for Medical Students
SLIDE 1 — What is Dyslipidemia?
Definition: An abnormality in the concentration or composition of circulating lipoproteins — including elevated LDL-C, low HDL-C, elevated triglycerides, or elevated Lp(a) — that increases ASCVD risk.
Types:
| Type | Description |
|---|---|
| ↑ LDL-C | Most common; primary target of therapy |
| ↓ HDL-C | Independent CV risk factor; lifestyle-modified |
| ↑ Triglycerides | Hypertriglyceridemia; pancreatitis risk at very high levels |
| ↑ Lp(a) | Genetically determined; newly emphasized in BOTH guidelines |
⚠ CVD is the #1 cause of death globally. Dyslipidemia is a major modifiable risk factor.
SLIDE 2 — Pathophysiology
Atherogenesis Cascade:
Elevated LDL-C / ApoB → Oxidation & Inflammation → Foam Cell Formation → Plaque Growth & Rupture
- LDL particles enter the subendothelial space; quantity is driven by ApoB (one per particle)
- Oxidized LDL activates endothelium → monocyte recruitment → macrophage infiltration
- Macrophages engulf ox-LDL → foam cells → fatty streak (earliest plaque lesion)
- Fibrous cap forms → plaque vulnerability → rupture → ACS / stroke / PAD
Key Atherogenic Particles (both guidelines):
| Particle | Role |
|---|---|
| LDL-C | Primary driver; each particle carries one ApoB |
| VLDL / IDL remnants | Triglyceride-rich remnant particles; highlighted in AHA 2026 |
| Lp(a) | Pro-atherogenic + pro-thrombotic; independent of LDL-C |
| Low HDL-C | Reduced reverse cholesterol transport; associated with higher ASCVD risk |
SLIDE 3 — Cardiovascular Risk Assessment
AHA 2026 — PREVENT-ASCVD Equations
- Replaces the 10-year Pooled Cohort Equations (PCE)
- Predicts 10-year AND 30-year ASCVD risk
- Variables: age, sex, race, BP, diabetes, smoking, kidney function, social deprivation, HbA1c, eGFR/uACR
- Better calibrated across diverse populations
- Used to guide initiation of pharmacotherapy in primary prevention
ESC 2025 — SCORE2 / SCORE2-OP
- SCORE2 for <70 years; SCORE2-OP for ≥70 years
- Estimates 10-year CV event risk (fatal + non-fatal)
- Region-calibrated (low / moderate / high / very high CV-risk countries)
- Risk modifiers refine the score: Lp(a), CAC, ABI, hsCRP, renal function
- Risk categories: Low → Moderate → High → Very High → Extreme (NEW)
- Replaces SCORE1 which only predicted CV mortality
SLIDE 4 — Screening & Diagnosis
Fasting Lipid Panel
- Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C
- Non-fasting acceptable for most screening scenarios
- Repeat 4-12 weeks after therapy initiation, then every 6-12 months
Lipoprotein(a) — Lp(a)
- AHA 2026: Universal adult screening ≥1× in a lifetime (Class I)
- ESC 2025: Measure in adults with CV risk assessment
- ≥50 mg/dL (≥125 nmol/L) = significant risk modifier
- Largely genetic; minimally affected by lifestyle changes
ApoB — Apolipoprotein B
- Each atherogenic particle carries exactly one ApoB → reflects particle number more accurately than LDL-C
- AHA 2026: Selective measurement to refine risk (especially when LDL-C and non-HDL-C disagree)
- Goal for very high risk: ApoB < 65 mg/dL | High risk: < 80 mg/dL
- ESC 2025 also endorses ApoB as an alternative treatment target
SLIDE 5 — AHA / ACC 2026: Key Updates
Published March 2026 in Circulation — Replaces the 2018 Blood Cholesterol Guideline
6 Major Changes
01 - PREVENT-ASCVD Equations
Replaces PCE; estimates 10- and 30-year risk; better calibrated across diverse populations; includes eGFR and metabolic variables.
02 - Restored LDL-C Goals
2018 guideline removed fixed targets — 2026 restores them. Very high risk: LDL-C <55; ASCVD not VHR: <70; primary prevention by risk level.
03 - Universal Lp(a) Screening
All adults should have Lp(a) measured ≥1× in a lifetime (Class I COR). Children with FH or family history: consider testing.
04 - Expanded CAC Scoring
CAC 0 = low near-term risk; CAC 1-99: goal <100; CAC 100-999 or ≥75th percentile: <70; CAC ≥1000: <55 mg/dL.
05 - Five New FDA-Approved Therapies
Inclisiran (siRNA PCSK9i), bempedoic acid, evinacumab (HoFH), pelacarsen (Lp(a)↓), olezarsen (TG↓) now incorporated.
06 - No Benefit: Dietary Supplements
Class 3 recommendation against fish oil, red yeast rice, plant sterols as routine ASCVD risk-reduction strategies.
SLIDE 6 — AHA 2026: LDL-C Treatment Goals by Risk
| Risk Category | LDL-C Goal | Non-HDL-C Goal |
|---|---|---|
| Secondary prevention — Very High Risk (≥2 major ASCVD events, or 1 event + ≥2 high-risk conditions) | < 55 mg/dL | < 85 mg/dL |
| Secondary prevention — Not Very High Risk | < 70 mg/dL | < 100 mg/dL |
| Primary prevention — Diabetes or multiple RF | < 70–100 mg/dL | < 100–130 mg/dL |
All patients: also target ≥50% LDL-C reduction from baseline
CAC Score → LDL-C Goal (Subclinical Atherosclerosis)
| CAC Score | Interpretation | LDL-C Goal |
|---|---|---|
| 0 AU | Very low near-term risk | Defer pharmacotherapy; lifestyle |
| 1-99 AU & <75th %ile | Mild subclinical disease | < 100 mg/dL |
| 100-999 AU or ≥75th %ile | Moderate-high subclinical | < 70 mg/dL |
| ≥ 1000 AU | Severe subclinical disease | < 55 mg/dL |
Very High Risk = ≥2 major ASCVD events OR 1 major event + ≥2 high-risk conditions (e.g., DM, CKD, HF, PAD, HTN, active smoking, age >65)
SLIDE 7 — ESC / EAS 2025: Key Updates
Published August 29, 2025 — Focused update of the 2019 ESC/EAS Guidelines
6 Major Changes
01 - LDL-C Targets Reaffirmed
Low: <116 | Moderate: <100 | High: <70 | Very High: <55 | Extreme (NEW): <40 mg/dL. "Lower is better" paradigm maintained.
02 - NEW: Extreme Risk Category ★
Patients with CVD + new vascular event despite max statin OR polyvascular disease → LDL-C goal <40 mg/dL.
03 - Fire-to-Target Strategy
Shift from stepwise to upfront combination therapy (statin + ezetimibe) — especially at ACS hospitalization. Speed to goal matters.
04 - Risk Modifiers Incorporated
Refine SCORE2 risk: Lp(a) ≥50 mg/dL, CAC score, ABI, hsCRP, T2DM duration, renal function, socioeconomic status.
05 - Bempedoic Acid Endorsed
For statin-intolerant patients; reduces LDL-C ~18%; reduces MACE (CLEAR Outcomes trial). Class I for CV event reduction.
06 - Special Populations Added
HIV patients and cancer therapy (cardio-oncology): statins recommended. Post-ACS: lipid-lowering during index hospitalization.
SLIDE 8 — ESC 2025: LDL-C Goals by Risk Category
| Risk Category | Definition | LDL-C Goal | % Reduction |
|---|---|---|---|
| Low | SCORE2 <5% | < 116 mg/dL | - |
| Moderate | SCORE2 5-10% | < 100 mg/dL | ≥30%↓ |
| High | SCORE2 10-20% or single major RF↑ | < 70 mg/dL | ≥50%↓ |
| Very High | SCORE2 ≥20% or established CVD | < 55 mg/dL | ≥50%↓ |
| Extreme ★ NEW | CVD + new event on max statin OR polyvascular | < 40 mg/dL | ≥50%↓ |
Combination therapy can reduce LDL-C by up to 86%: High-intensity statin (↓55%) + Ezetimibe (additional ↓24%) + PCSK9 inhibitor (additional ↓60% on top of statin)
SLIDE 9 — Lifestyle Modifications
Foundation of therapy in ALL risk categories — both guidelines agree
🥗 Diet
- Mediterranean or DASH diet
- Reduce saturated fat <7% of calories; avoid trans fats entirely
- Increase soluble fiber (10-25 g/day)
- Plant sterols 2 g/day reduce LDL-C ~5-10%
🏃 Physical Activity
- ≥150 min/week moderate-intensity aerobic OR ≥75 min/week vigorous
- Resistance training 2×/week
- Reduces TG, raises HDL-C
⚖️ Weight Management
- 5-10% weight loss → LDL-C ↓5-8 mg/dL; significantly reduces TG
- Target BMI <25 kg/m²
- Bariatric surgery in refractory obesity
🚭 Smoking & Alcohol
- Smoking cessation → HDL-C ↑4-8 mg/dL; reduces ASCVD risk significantly
- Limit alcohol: ≤1 drink/day women, ≤2 men
- Heavy alcohol → severe hypertriglyceridemia
SLIDE 10 — Pharmacotherapy
| Drug Class | LDL-C Reduction | Mechanism | Key Points |
|---|---|---|---|
| Statins (HMG-CoA reductase inhibitors) | 30-55%↓ | Inhibit cholesterol synthesis → upregulate LDL receptors | FIRST-LINE in both guidelines; rosuvastatin / atorvastatin high-intensity |
| Ezetimibe | 18-24%↓ | Inhibits NPC1L1 → reduces intestinal cholesterol absorption | Add-on to statin; ESC 2025 recommends upfront combination (IMPROVE-IT) |
| PCSK9 Inhibitors (evolocumab, alirocumab) | 50-65%↓ | Block PCSK9 → prevent LDL receptor degradation | SC injection q2w or monthly; for very high/extreme risk not at goal |
| Bempedoic Acid | ~18%↓ | ATP-citrate lyase inhibitor; activated only in liver | Statin-intolerant; CLEAR Outcomes trial; ESC 2025 Class I |
| Inclisiran (siRNA) | ~50%↓ | Silences PCSK9 mRNA in hepatocytes | Dosing: 0, 3 months → then q6 months SC; AHA 2026 second-line after mAb |
| Fibrates / EPA | TG ↓30-50% | PPAR-α agonists; EPA only — REDUCE-IT | Icosapentaenoic acid 4 g/day; TG ≥500 mg/dL (pancreatitis risk) |
SLIDE 11 — Treatment Algorithm
STEP 1 — Lifestyle Modifications
Diet, exercise, weight loss, smoking cessation → ALL patients
↓ if LDL-C goal not met
STEP 2 — High-Intensity Statin
Rosuvastatin 20-40 mg OR Atorvastatin 40-80 mg → ≥50% LDL-C reduction
↓ if LDL-C goal not met
STEP 3 — Add Ezetimibe
10 mg/day add-on
ESC 2025: Consider upfront statin + ezetimibe (fire-to-target)
↓ if LDL-C goal not met
STEP 4 — Add PCSK9 Inhibitor
Evolocumab or alirocumab (SC injection)
AHA 2026: No longer strictly sequential — choose by LDL-C gap needed
↓ if statin-intolerant
STEP 5 — Alternatives for Statin Intolerance
Bempedoic acid ± ezetimibe
Inclisiran as alternative to PCSK9 mAb
Evinacumab for homozygous FH (HoFH)
Monitor lipid profile 4-12 weeks after therapy change, then every 6-12 months. Therapeutic inertia is a key barrier — intensify until goals are achieved.
SLIDE 12 — Special Populations
Diabetes Mellitus (T2DM)
- High-intensity statin recommended even without clinical ASCVD
- LDL-C <70 mg/dL for high-risk DM; <55 for very high risk
- AHA 2026: PREVENT incorporates HbA1c in risk calculation
- GLP-1 agonists / SGLT2i reduce ASCVD events independently
Familial Hypercholesterolemia (FH)
- Universal childhood lipid screening: AHA 2026 ages 9-11; ESC 2025 ages 5-10
- Heterozygous FH: LDL-C >190 mg/dL despite lifestyle → high-intensity statin
- Homozygous FH: Evinacumab (anti-ANGPTL3) + LDL apheresis
- Cascade screening of all first-degree relatives recommended
Elderly (≥75 years)
- SCORE2-OP used in ESC 2025 for those ≥70 years
- Statins remain beneficial in secondary prevention regardless of age
- Primary prevention: individualize; risk of adverse effects increases with age
- Polypharmacy and drug interactions must be considered
HIV & Cardio-Oncology (ESC 2025 NEW)
- Statins recommended in HIV patients at CV risk
- Cancer therapy (anthracyclines, checkpoint inhibitors) → increased CV risk
- Rosuvastatin and pravastatin preferred (fewer drug interactions with ART)
- Monitor CYP3A4 interactions between ART and statins
SLIDE 13 — AHA 2026 vs ESC 2025: Side-by-Side
| Feature | AHA / ACC 2026 | ESC / EAS 2025 |
|---|---|---|
| Risk tool | PREVENT-ASCVD (10- & 30-yr) | SCORE2 / SCORE2-OP |
| Risk categories | Primary, secondary, very high risk | Low / Moderate / High / Very High / Extreme |
| Lowest LDL-C target | < 55 mg/dL (very high risk) | < 40 mg/dL (extreme risk) ★ |
| Lp(a) screening | Universal (Class I) | Recommended in risk assessment |
| ApoB | Selective — refine risk | Endorsed as alternative target |
| CAC scoring | Expanded role in primary prevention | Risk modifier to refine SCORE2 |
| Treatment approach | PCSK9i no longer strictly sequential | Fire-to-target — upfront combination |
| Statin intolerance | Bempedoic acid, inclisiran | Bempedoic acid Class I (CLEAR Outcomes) |
| Dietary supplements | Class 3 — NOT recommended | Not recommended |
| Childhood screening | Ages 9-11 (FH cascade) | Ages 5-10 (FH cascade) |
| New drug classes | Inclisiran, pelacarsen, olezarsen | Bempedoic acid, evinacumab |
| Published | March 2026 — Circulation | August 2025 — Eur Heart J |
★ Extreme Risk is unique to ESC 2025 — no equivalent category exists in AHA 2026
SLIDE 14 — Hypertriglyceridemia
Classification
| Category | TG Level |
|---|---|
| Normal | < 150 mg/dL |
| Borderline High | 150-199 mg/dL |
| High | 200-499 mg/dL |
| Very High | ≥ 500 mg/dL |
Common Causes
- Obesity and metabolic syndrome
- Type 2 diabetes / insulin resistance
- Hypothyroidism, Cushing syndrome
- Chronic kidney disease / nephrotic syndrome
- Excessive alcohol consumption
- Medications: thiazides, beta-blockers, isotretinoin, HIV ART, estrogens
- Familial hypertriglyceridemia (genetic)
Management
- Lifestyle: weight loss, reduce refined carbs, limit alcohol
- Treat secondary causes (glycemic control, thyroid)
- If TG ≥500 mg/dL → fibrates first (pancreatitis risk)
- Icosapentaenoic acid (EPA) 4 g/day — REDUCE-IT trial: ↓25% MACE
- AHA 2026: remnant particles highlighted as independent ASCVD risk
- Non-HDL-C is a better treatment target than TG directly
SLIDE 15 — Lipoprotein(a): The Emerging Biomarker
Lp(a) = LDL-like particle + apolipoprotein(a). Levels are >90% genetically determined; minimally modified by diet or lifestyle. Elevated Lp(a) independently increases risk of MI, stroke, aortic stenosis, and PAD.
| AHA 2026 | ESC 2025 | |
|---|---|---|
| Screening | Class I — Measure ≥1× in all adults | Recommended in CV risk assessment |
| Threshold | ≥75 nmol/L (risk modifier); ≥125 nmol/L (high risk) | ≥50 mg/dL = significant risk modifier |
| Treatment target | Not yet defined | Not yet defined (target expected in future guidelines) |
| PCSK9i effect | Modest ↓20-25% on Lp(a) | Modest ↓20-25% on Lp(a) |
| Pipeline drug | Pelacarsen (antisense oligo) → ↓80% Lp(a); Phase 3 awaiting CV outcome data | Olezarsen being studied (Lp(a) + TG) |
SLIDE 16 — Monitoring & Statin Safety
Follow-up Schedule
| Timepoint | What to Check |
|---|---|
| Baseline | Fasting lipids, LFTs, CK, glucose, HbA1c, Lp(a) once |
| 4-12 weeks | Repeat lipid panel; assess % LDL-C reduction; CK if myalgia |
| Every 6-12 months | Ongoing lipid monitoring once at goal; tolerability; adherence |
| Annually | Reassess CV risk; intensify if goals not met; specialist referral |
Statin Safety
| Concern | Key Points |
|---|---|
| Myopathy / Rhabdomyolysis | 0.1-0.5% incidence; CK >10× ULN → stop statin; check for interactions (CYP3A4), hypothyroidism, CKD |
| New-onset Diabetes | Modest risk (~10-12%); ASCVD risk reduction far outweighs this in high-risk patients |
| LFT Elevation | Severe hepatotoxicity is rare; baseline LFTs; recheck only if symptomatic |
| Cognitive Effects | No consistent evidence; concern not substantiated in large trials |
SLIDE 17 — 10 Take-Home Messages
| # | Key Message | Summary |
|---|---|---|
| 1 | Dyslipidemia = more than LDL-C | Lp(a), remnant particles, and ApoB all contribute to ASCVD risk |
| 2 | AHA 2026 restores LDL-C goals | Very high risk <55; ASCVD not VHR <70 mg/dL; plus ≥50% reduction target |
| 3 | ESC 2025 adds Extreme Risk | New category: LDL-C <40 mg/dL for CVD + recurrent event on max therapy |
| 4 | Universal Lp(a) screening | AHA 2026 Class I for all adults; ESC 2025 strongly recommended |
| 5 | PREVENT replaces PCE in the USA | Better calibrated; integrates 10- and 30-year risk; includes metabolic/renal variables |
| 6 | Fire-to-target (ESC) vs sequential (AHA) | ESC supports upfront statin + ezetimibe; AHA allows simultaneous PCSK9i add-on |
| 7 | Statin + Ezetimibe + PCSK9i = up to 85% LDL-C reduction | Combination therapy is highly effective; bempedoic acid for statin-intolerant |
| 8 | Lifestyle always comes first | Diet, exercise, smoking cessation — recommended in ALL risk categories |
| 9 | No dietary supplements | Both guidelines: Class 3 / not recommended for fish oil, red yeast rice, plant sterols |
| 10 | Overcome therapeutic inertia | Follow-up at 4-12 weeks; intensify until goals are achieved; refer to lipid specialist if needed |
References
- Blumenthal RS, Morris PB et al. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. March 2026.
- Mach F, Baigent C, Catapano AL et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. August 2025.
- Lloyd-Jones DM et al. PREVENT-ASCVD Equations. Circulation. 2024.
- Nissen SE et al. Bempedoic acid and cardiovascular outcomes — CLEAR Outcomes. NEJM. 2023.
- Ridker PM et al. Inclisiran — ORION-10 & ORION-11 trials. NEJM. 2020.
- Bhatt DL et al. Cardiovascular risk reduction with icosapentaenoic acid — REDUCE-IT. NEJM. 2019.
That covers all 17 content slides in full. The structure follows: definition → pathophysiology → risk tools → screening → AHA 2026 updates → ESC 2025 updates → treatment (lifestyle, drugs, algorithm) → special populations → comparison table → hypertriglyceridemia → Lp(a) → monitoring → summary. Let me know if you want to expand any specific section.
Give me history taking list all for gout patient
Here is a complete history-taking checklist for a gout patient:
🩺 History Taking — Gout Patient
Complete Structured Checklist
1. PRESENTING COMPLAINT (PC)
- Joint pain — which joint(s)?
- Swelling, redness, warmth
- Duration of current episode
- Onset: sudden vs gradual
2. HISTORY OF PRESENTING COMPLAINT (HPC)
Pain Characterization (SOCRATES)
- Site: Which joint(s) — 1st MTP (podagra), ankle, knee, wrist, elbow, finger
- Onset: Sudden overnight onset? (classic gout pattern)
- Character: Burning, throbbing, crushing, aching
- Radiation: Spreading to other joints?
- Associated symptoms (see below)
- Timing: Constant or intermittent? Morning vs night?
- Exacerbating factors: Walking, touch, light pressure (even bedsheet intolerance?)
- Severity: Pain score 1-10; ability to weight-bear?
Attack Features
- How many hours from onset to peak severity?
- Hyperemia (intense redness) over joint?
- Desquamation (skin peeling) after attack?
- Can you bear weight on the joint?
- Any fever or systemic symptoms during attack?
- How long does each attack last untreated?
- Complete resolution between attacks?
3. GOUT ATTACK HISTORY
- Age at first attack
- Total number of attacks
- Frequency of attacks (per year)
- Pattern — same joint each time or migrating?
- Any polyarticular attacks (multiple joints at once)?
- Longest pain-free interval between attacks
- Are attacks getting more frequent or severe over time?
- Any attacks at night specifically?
- Any spontaneous resolution?
4. PRECIPITATING / TRIGGER FACTORS
Dietary Triggers (ask specifically)
- Red meat (beef, lamb, pork)
- Organ meats (liver, kidney, sweetbreads, brain)
- Seafood / shellfish (especially anchovies, sardines, mussels, scallops, shrimp)
- Alcohol — type and quantity:
- Beer (highest purine content)
- Spirits / whisky
- Wine (lower risk but still ask)
- Sugary drinks / fructose-containing beverages (sodas, fruit juices)
- High-fructose corn syrup foods
Other Triggers
- Recent illness, infection, or surgery (physiological stress)
- Dehydration (recent fasting, poor fluid intake, hot weather)
- Recent initiation of diuretics
- Recent initiation of allopurinol or urate-lowering therapy (can trigger acute flare)
- Trauma to joint
- Excessive exercise
- Crash dieting / starvation
- Blood transfusion or chemotherapy (cell lysis → purine release)
5. INTERVAL / INTERCRITICAL PERIOD
- Any joint symptoms between attacks?
- Joint stiffness between episodes?
- Full return to normal function?
- Duration of the pain-free intervals (becoming shorter?)
6. CHRONIC TOPHACEOUS GOUT
- Any lumps or nodules over joints, ears, tendons?
- Ask specifically about:
- Ear pinnae (helix / antihelix)
- Fingers / knuckles
- Elbow (olecranon bursa)
- Achilles tendon
- First MTP joint
- Forearm
- White chalky discharge from any lumps?
- Ulceration over lumps?
- Joint deformity?
- Functional limitation of any joint?
7. URINARY / RENAL SYMPTOMS
- Kidney stones (uric acid nephrolithiasis) — ever passed a stone?
- Flank / loin pain (renal colic)
- Hematuria (blood in urine)
- Recurrent urinary tract infections
- Reduced urine output / foamy urine
- Known chronic kidney disease?
- Any prior renal ultrasound or CT for stones?
8. PAST MEDICAL HISTORY (PMH)
- Hyperuricemia — known elevated serum uric acid? Previous readings?
- Hypertension — very strong association with gout
- Type 2 Diabetes Mellitus / Metabolic Syndrome
- Dyslipidemia (ask — links to metabolic syndrome)
- Obesity — weight history, BMI
- Chronic Kidney Disease — stage, GFR
- Cardiovascular disease — IHD, heart failure, stroke
- Psoriasis (associated with hyperuricemia)
- Haematological malignancy — leukemia, lymphoma, polycythemia (high cell turnover)
- Hypothyroidism (reduces uric acid excretion)
- Organ transplant (cyclosporine use → hyperuricemia)
- Previous joint disease — OA, RA, septic arthritis
- Renal transplant (especially — cyclosporine → gout very common)
9. DRUG HISTORY (DH)
Drugs that RAISE Uric Acid (ask about each)
| Drug | Mechanism |
|---|---|
| Thiazide diuretics (hydrochlorothiazide, bendroflumethiazide) | Reduce renal uric acid excretion |
| Loop diuretics (furosemide, bumetanide) | Reduce renal uric acid excretion |
| Low-dose aspirin (<2 g/day) | Reduces uric acid secretion |
| Ciclosporin / Tacrolimus | Reduce renal clearance of urate |
| Pyrazinamide (TB drug) | Inhibits uric acid excretion |
| Ethambutol | Reduces renal uric acid excretion |
| Levodopa | Can raise uric acid levels |
| Beta-blockers | Mildly raise uric acid |
| Nicotinic acid / Niacin | Competes with uric acid excretion |
| Chemotherapy agents | Tumor lysis → massive purine release |
Current Gout Medications
- On allopurinol? Dose? How long?
- On febuxostat? Dose?
- On probenecid or benzbromarone?
- On colchicine (prophylaxis)?
- NSAIDs used during attacks? Which ones?
- Corticosteroids for acute attacks?
Other Current Medications
- ACE inhibitors / ARBs (losartan is uricosuric — beneficial)
- Metformin, SGLT2 inhibitors (mildly uricosuric)
- Statins
- Any over-the-counter medications / supplements?
- Vitamin C supplements (mildly lowers urate)
Allergies
- Drug allergies — especially allopurinol hypersensitivity (Stevens-Johnson syndrome risk, HLA-B*5801 association in Asian patients)
- NSAID allergy / intolerance
10. FAMILY HISTORY (FH)
- Family history of gout (first-degree relatives)?
- Family history of kidney stones?
- Family history of hyperuricemia?
- Any rare inherited conditions:
- Lesch-Nyhan syndrome (HGPRT deficiency — young males, severe hyperuricemia)
- Kelley-Seegmiller syndrome
- Familial juvenile hyperuricemic nephropathy (FJHN)
- PRPP superactivity
11. SOCIAL HISTORY (SH)
Alcohol
- Type, frequency, and quantity per week
- CAGE questionnaire if concerned
- Recent binge drinking before this attack?
Diet
- Red meat / organ meat consumption frequency
- Seafood frequency
- Soft drink / fizzy drink intake
- Dairy intake (dairy is protective — ask)
- Fluid / water intake per day (dehydration is a trigger)
- Coffee intake (mildly protective)
- Recent dietary changes / crash diet?
Occupation
- Type of work — manual labor (joint trauma)?
- Work schedule — night shifts (eating patterns, hydration)
- Occupational exposures (lead exposure → saturnine gout)
Lifestyle
- Smoking status
- BMI / weight history — recent weight gain?
- Exercise habits
- Recent travel or change in diet?
Social Circumstances
- Living situation, support at home
- Impact of gout on activities of daily living (ADLs)
- Ability to work / mobility during attacks
- Psychological impact — anxiety, depression?
12. SYSTEMS REVIEW (SR)
Musculoskeletal
- Joint stiffness (morning stiffness duration?)
- Other joint involvement — asymmetric? Symmetric?
- Muscle weakness
- Bone pain
Renal
- Urine output, color, frothiness
- Flank pain, dysuria
- Known renal stones
Cardiovascular
- Chest pain, palpitations, shortness of breath
- Ankle swelling (CKD / heart failure)
Gastrointestinal
- Nausea, vomiting, diarrhea
- GI upset with NSAIDs or colchicine
- Peptic ulcer disease (relevant if considering NSAIDs)
Skin
- Rashes, tophi, ulceration
- Psoriatic plaques
Systemic
- Fever, chills (rule out septic arthritis)
- Fatigue, weight loss (haematological malignancy?)
- Night sweats
13. FUNCTIONAL IMPACT
- Can the patient walk during an attack?
- Time off work due to gout?
- Sleep disturbance from pain?
- Ability to wear normal footwear?
- Impact on social life / activities?
- How is the patient coping emotionally?
14. PATIENT'S IDEAS, CONCERNS & EXPECTATIONS (ICE)
- Ideas: What does the patient think is causing their symptoms?
- Concerns: What worries them most? (damage, disability, long-term medication)
- Expectations: What do they hope to achieve today? Pain relief? Diagnosis? Long-term prevention?
- Understanding of gout and uric acid?
- Previous advice given — has it been followed?
- Willingness to change diet / lifestyle?
Quick Reference Summary Table
| Domain | Key Questions |
|---|---|
| Site & onset | Which joint? Sudden overnight? |
| Attack pattern | Frequency, duration, complete resolution? |
| Triggers | Diet (meat, seafood, alcohol, fructose), drugs, dehydration |
| Tophi | Ears, elbows, tendons, MTP joint — any nodules? |
| Renal | Stones, hematuria, CKD |
| PMH | HTN, DM, CKD, CVD, malignancy |
| Drugs | Diuretics, aspirin, cyclosporin, allopurinol |
| Family Hx | Gout, stones, Lesch-Nyhan |
| Social | Alcohol, diet, occupation (lead?), ADL impact |
| ICE | Ideas, concerns, expectations |
This covers every domain needed for a thorough gout history. Let me know if you want me to format this as a printable PDF or structured examination card.
What are the questions need to ask for gout patient to diagnosis and make a medical record
Here are the exact questions to ask a gout patient during clinical consultation, organized as you would say them to the patient:
🩺 Gout Patient — Clinical Interview Questions
Exact Questions for Diagnosis & Medical Record
🔴 OPENING
"What brought you in today?" "Tell me about the pain you are having."
1. PRESENTING JOINT PAIN
| # | Question | What You Are Looking For |
|---|---|---|
| 1 | "Which joint is painful?" | 1st MTP (podagra = classic gout) |
| 2 | "Is it one joint or multiple joints?" | Monoarthritis vs polyarthritis |
| 3 | "When exactly did the pain start?" | Sudden overnight onset = classic |
| 4 | "How quickly did it reach its worst?" | Hours = gout; days = other arthritis |
| 5 | "On a scale of 1–10, how bad is the pain?" | Gout is typically 8–10/10 |
| 6 | "What does the pain feel like? Burning? Throbbing? Crushing?" | Burning/throbbing = typical gout |
| 7 | "Does the pain spread anywhere?" | Radiation pattern |
| 8 | "Is the joint swollen or red?" | Signs of acute inflammation |
| 9 | "Is the joint warm to touch?" | Warmth = acute crystal arthritis |
| 10 | "Does even a light touch — like a bedsheet — hurt the joint?" | Hyperalgesia = hallmark of gout |
| 11 | "Can you walk / bear weight on it?" | Functional severity |
| 12 | "What makes it worse? What makes it better?" | Ice, rest, elevation |
2. ATTACK PATTERN & HISTORY
| # | Question | What You Are Looking For |
|---|---|---|
| 13 | "Have you had this kind of pain before?" | Recurrent attacks = gout pattern |
| 14 | "How old were you when it first happened?" | Early onset → consider genetic cause |
| 15 | "How many times has this happened?" | Frequency of attacks |
| 16 | "How often do attacks occur — once a year? Monthly?" | Attack frequency = disease progression |
| 17 | "Does the same joint get affected each time?" | Same joint = typical; migrating = polyarticular |
| 18 | "How long does each attack last?" | Gout: days to 2 weeks |
| 19 | "Does the pain completely go away between attacks?" | Complete resolution = intermittent gout |
| 20 | "Are the attacks getting more frequent or more severe over time?" | Disease progression to chronic gout |
| 21 | "Did the skin ever peel or flake over the joint after the attack?" | Post-attack desquamation = gout sign |
| 22 | "Did you have fever during the attack?" | Rule out septic arthritis |
3. TRIGGER FACTORS
| # | Question | What You Are Looking For |
|---|---|---|
| 23 | "Did anything happen just before this attack started?" | Identify trigger |
| 24 | "Did you eat a lot of red meat, organ meat, or seafood recently?" | High-purine food trigger |
| 25 | "Did you drink alcohol — especially beer — before the attack?" | Beer = highest purine content |
| 26 | "Did you drink a lot of sugary drinks or soda recently?" | Fructose → hyperuricemia |
| 27 | "Were you unwell, had a fever, or had surgery recently?" | Physiological stress trigger |
| 28 | "Did you drink enough water? Were you dehydrated?" | Dehydration = common trigger |
| 29 | "Did you start any new medication recently?" | Diuretics, aspirin, cyclosporin |
| 30 | "Did you recently start allopurinol or gout tablets?" | ULT initiation can trigger flare |
| 31 | "Did you injure or trauma the joint recently?" | Trauma trigger |
4. TOPHI (CHRONIC GOUT)
| # | Question | What You Are Looking For |
|---|---|---|
| 32 | "Have you noticed any lumps or bumps around your joints, elbows, or ears?" | Tophi = chronic tophaceous gout |
| 33 | "Have any of these lumps ever discharged a white chalky material?" | Urate crystal discharge from tophus |
| 34 | "Do you have any ulcers or sores over the lumps?" | Tophus ulceration |
| 35 | "Have your joints changed shape or become deformed?" | Chronic joint destruction |
5. KIDNEY / URINARY SYMPTOMS
| # | Question | What You Are Looking For |
|---|---|---|
| 36 | "Have you ever had kidney stones?" | Uric acid nephrolithiasis |
| 37 | "Have you ever had severe pain in your side or back that came in waves?" | Renal colic |
| 38 | "Have you noticed blood in your urine?" | Hematuria from stones |
| 39 | "Have you had recurrent urine infections?" | CKD / nephrolithiasis complication |
| 40 | "Have you been told your kidneys are not working well?" | CKD — affects urate excretion and drug choice |
6. PAST MEDICAL HISTORY
| # | Question | What You Are Looking For |
|---|---|---|
| 41 | "Have you been told your uric acid is high?" | Asymptomatic hyperuricemia history |
| 42 | "Do you have high blood pressure?" | HTN = strong gout association; diuretics used |
| 43 | "Do you have diabetes?" | Metabolic syndrome cluster |
| 44 | "Do you have high cholesterol?" | Metabolic syndrome |
| 45 | "Have you had a heart attack or stroke?" | Cardiovascular comorbidity |
| 46 | "Do you have heart failure?" | Affects diuretic use and treatment choice |
| 47 | "Do you have kidney disease?" | Affects drug dosing (allopurinol, NSAIDs) |
| 48 | "Do you have psoriasis?" | Associated with hyperuricemia |
| 49 | "Have you ever had a cancer of the blood — leukemia, lymphoma?" | High cell turnover → hyperuricemia |
| 50 | "Have you had a joint replaced or any joint surgery?" | Surgical history |
| 51 | "Have you had an organ transplant?" | Cyclosporine → severe hyperuricemia |
| 52 | "Do you have an underactive thyroid?" | Hypothyroidism reduces urate excretion |
| 53 | "Do you have any other medical conditions I should know about?" | Open-ended catch-all |
7. DRUG HISTORY
| # | Question | What You Are Looking For |
|---|---|---|
| 54 | "What medications are you currently taking — including tablets, injections, and inhalers?" | Full drug list |
| 55 | "Are you taking any water tablets (diuretics)?" | Thiazides/loops → hyperuricemia |
| 56 | "Do you take aspirin — even a small daily dose?" | Low-dose aspirin ↑ uric acid |
| 57 | "Are you on any anti-rejection medications?" | Cyclosporin / tacrolimus |
| 58 | "Are you on any tuberculosis medications?" | Pyrazinamide / ethambutol → ↑ urate |
| 59 | "Are you currently taking allopurinol or febuxostat?" | ULT compliance and dosing |
| 60 | "Are you taking colchicine — for prevention or during attacks?" | Prophylaxis assessment |
| 61 | "What do you take during a gout attack — any painkillers?" | NSAIDs, steroids, colchicine use |
| 62 | "Do you take any over-the-counter medications, herbal, or supplements?" | Vitamin C, fish oil, complementary medicine |
| 63 | "Do you have any drug allergies?" | Especially allopurinol hypersensitivity (SJS risk) |
| 64 | "Have you ever had a bad reaction to any medication?" | Adverse drug reactions |
8. FAMILY HISTORY
| # | Question | What You Are Looking For |
|---|---|---|
| 65 | "Does anyone in your family — parents, siblings — have gout?" | Genetic predisposition |
| 66 | "Does anyone in the family have kidney stones?" | Familial uric acid nephrolithiasis |
| 67 | "Is there any family history of early kidney disease?" | FJHN (Familial juvenile hyperuricemic nephropathy) |
9. SOCIAL HISTORY
| # | Question | What You Are Looking For |
|---|---|---|
| 68 | "Do you drink alcohol? How much and how often?" | Alcohol intake — type and quantity |
| 69 | "Which type of alcohol do you drink most — beer, wine, or spirits?" | Beer = highest risk |
| 70 | "Have you increased your drinking recently?" | Recent change in consumption |
| 71 | "What does a typical day of eating look like for you?" | Dietary pattern assessment |
| 72 | "How often do you eat red meat, shellfish, or organ meats?" | Purine-rich food frequency |
| 73 | "How much water do you drink per day?" | Hydration status |
| 74 | "Do you smoke?" | Smoking history |
| 75 | "What is your job / occupation?" | Lead exposure? Physical demands? |
| 76 | "Have you been exposed to lead at work or at home?" | Saturnine gout (lead → ↓ urate excretion) |
| 77 | "How much do you weigh? Has your weight changed recently?" | Obesity = risk factor; weight gain = trigger |
| 78 | "Do you exercise regularly?" | Activity level |
10. FUNCTIONAL IMPACT
| # | Question | What You Are Looking For |
|---|---|---|
| 79 | "How has this affected your ability to walk and do daily activities?" | Functional disability |
| 80 | "Have you had to take time off work because of gout?" | Occupational impact |
| 81 | "Can you wear normal shoes during an attack?" | 1st MTP involvement impact |
| 82 | "How is your sleep affected during an attack?" | Pain affecting sleep |
| 83 | "How has gout affected your life overall?" | Quality of life |
11. ICE — Ideas, Concerns & Expectations
| # | Question | Purpose |
|---|---|---|
| 84 | "What do you think is causing this pain?" | Patient's own understanding |
| 85 | "Is there anything specific you are worried about?" | Uncover hidden concerns |
| 86 | "What were you hoping we could do for you today?" | Align management with expectations |
| 87 | "Has anyone explained gout to you before? What do you understand about it?" | Assess health literacy |
| 88 | "Are you willing to make some changes to your diet and lifestyle?" | Assess readiness to change |
🔵 DIAGNOSTIC CHECKLIST — What to Document
After the interview, your medical record should capture:
DATE OF CONSULTATION:
PATIENT: Age / Sex / Ethnicity (HLA-B*5801 relevant in Asian patients)
PC: Joint pain — [joint name], [duration]
HPC:
- Site: _______________
- Onset: Sudden / Gradual
- Duration of current attack: ___ days
- Severity: ___/10
- Character: _______________
- Hyperalgesia (bedsheet sign): Yes / No
- Trigger identified: _______________
- Number of previous attacks: ___
- Attack frequency: ___/year
- Complete resolution between attacks: Yes / No
- Tophi present: Yes / No — Location: _______________
- Renal stones: Yes / No
PMH: HTN / DM / Dyslipidemia / CKD / CVD / Psoriasis / Malignancy / Transplant
DH: [List all medications]
Urate-raising drugs: Yes / No — _______________
Current ULT: Yes / No — Drug/Dose: _______________
Allergies: _______________
FH: Gout / Renal stones / Kidney disease
SH: Alcohol: ___ units/week (type: ___)
Diet: High purine? ___
Smoking: ___
Occupation: ___
Lead exposure: Yes / No
FUNCTIONAL STATUS: _______________
ICE: _______________
SYSTEMS REVIEW: _______________
🟡 KEY DIAGNOSTIC POINTERS FROM HISTORY
| History Finding | Suggests |
|---|---|
| Sudden overnight severe monoarthritis of 1st MTP | Classic podagra = gout until proven otherwise |
| Complete resolution between attacks | Intermittent gouty arthritis |
| Attacks triggered by alcohol / red meat | Dietary-induced hyperuricemia |
| Bedsheet hyperalgesia | Acute crystal arthritis |
| Tophi on ears, elbows, tendons | Chronic tophaceous gout |
| On thiazide diuretic + joint pain | Drug-induced hyperuricemia → gout |
| Renal stones + joint pain | Uric acid nephrolithiasis |
| Young male + very high uric acid + neurological symptoms | Lesch-Nyhan syndrome |
| Transplant patient + gout | Cyclosporine-induced hyperuricemia |
| Fever + single joint | Must exclude septic arthritis first |
This is everything you need to conduct a complete, diagnosis-oriented gout consultation and fill a medical record. Let me know if you want this as a printable form or OSCE-style checklist.
From AHA 2026 guidelines I need a topic presentation in dyslipidemia give me , intro ,epidemiology, pathophysiology, clinical features, lab investigation, diagnostic criteria and classification, risk factors, treatment and management ( pharmacological and non - pharmacological)
Here is the complete topic presentation based on AHA 2026 guidelines:
🫀 DYSLIPIDEMIA
A Complete Topic Presentation
Based on AHA / ACC 2026 Guidelines
PART 1 — INTRODUCTION
Definition
Dyslipidemia is an abnormality in the concentration, composition, or metabolism of circulating lipoproteins — including:
- Elevated LDL-C (low-density lipoprotein cholesterol)
- Elevated non-HDL-C
- Elevated triglycerides (TG)
- Elevated lipoprotein(a) [Lp(a)]
- Low HDL-C (high-density lipoprotein cholesterol)
These abnormalities independently and collectively increase the risk of atherosclerotic cardiovascular disease (ASCVD).
Why It Matters — AHA 2026 Context
The 2026 ACC/AHA Guideline replaces and retires the 2018 Blood Cholesterol Guideline. The key conceptual shift:
| 2018 Guideline | 2026 Guideline |
|---|---|
| Focus on LDL-C alone | Broader focus: LDL-C + remnant particles + Lp(a) + ApoB |
| No fixed LDL-C targets | Restores absolute LDL-C treatment goals |
| Pooled Cohort Equations (PCE) | PREVENT-ASCVD Equations |
| Statins only emphasized | Multi-pathway lipid management |
| Treating a number | Treating lifetime cardiovascular risk |
The guideline is retitled from "Blood Cholesterol" to "Management of Dyslipidemia" — reflecting that ASCVD risk extends beyond LDL-C to include triglyceride-rich remnants and Lp(a).
Lipoprotein Structure — Brief Review
Lipoproteins are transport vehicles for lipids in the bloodstream. Each is classified by density and lipid content:
| Lipoprotein | Primary Lipid | Apolipoprotein | Atherogenicity |
|---|---|---|---|
| Chylomicrons | Dietary TG | ApoB-48 | Low (too large to enter wall) |
| VLDL | Endogenous TG | ApoB-100 | Moderate (remnants are) |
| IDL | TG + Cholesterol | ApoB-100 | High |
| LDL | Cholesterol | ApoB-100 | High — primary target |
| HDL | Cholesterol (reverse) | ApoA-I | Protective |
| Lp(a) | Cholesterol + apo(a) | ApoB-100 + apo(a) | High — independent risk |
AHA 2026 key principle: Every atherogenic particle carries exactly one ApoB molecule. ApoB is therefore a more accurate measure of atherogenic particle number than LDL-C alone.
PART 2 — EPIDEMIOLOGY
Global Burden
- Cardiovascular disease (CVD) is the #1 cause of death globally, accounting for ~18 million deaths per year (WHO, 2024)
- Dyslipidemia is present in approximately 50% of adults worldwide
- Elevated LDL-C is estimated to cause 4.4 million deaths annually
- Only one-third of individuals with dyslipidemia are aware of their condition
- Only one-fifth of those aware are adequately treated
United States (AHA 2026 Data)
- ~94 million U.S. adults (age ≥20) have total cholesterol ≥200 mg/dL
- ~28% of U.S. adults have LDL-C ≥130 mg/dL
- ~25% of U.S. adults have low HDL-C (<40 mg/dL men, <50 mg/dL women)
- ~25% have hypertriglyceridemia (TG ≥150 mg/dL)
- ~20% of the population has elevated Lp(a) ≥50 mg/dL
- Hypertriglyceridemia affects ~1 in 4 American adults
- Despite statin availability, only ~55% of very-high-risk patients achieve LDL-C goals
Demographic Patterns
| Group | Pattern |
|---|---|
| Men | Higher LDL-C at younger age; earlier ASCVD onset |
| Women | LDL-C rises after menopause; catch up to men post-50 |
| South Asian | Higher Lp(a), higher TG, lower HDL-C; greater ASCVD risk at same LDL-C |
| Black Americans | Higher Lp(a) levels; higher HTN prevalence |
| Hispanic Americans | Higher TG, lower HDL-C; higher metabolic syndrome prevalence |
| Elderly | Higher prevalence dyslipidemia; but underdiagnosed and undertreated |
Pediatric Epidemiology
- AHA 2026 recommends universal lipid screening for children ages 9–11 years
- Familial hypercholesterolemia (FH) affects ~1 in 250 persons worldwide
- FH is one of the most common genetic disorders but remains >90% undiagnosed
- Childhood hypercholesterolemia accelerates atherosclerosis beginning in the first decade of life (Bogalusa Heart Study)
PART 3 — PATHOPHYSIOLOGY
Overview of Normal Lipid Metabolism
Exogenous Pathway (Dietary Lipids)
- Dietary fat absorbed in gut → packaged into chylomicrons (contain ApoB-48)
- Chylomicrons enter lymphatics → circulation → deliver TG to muscles and adipose tissue via lipoprotein lipase (LPL)
- Chylomicron remnants taken up by liver via ApoE receptor
Endogenous Pathway (Hepatic Lipids)
- Liver synthesizes TG and cholesterol → packaged into VLDL (contain ApoB-100)
- LPL in peripheral tissues hydrolyzes VLDL TG → VLDL becomes IDL, then LDL
- LDL delivers cholesterol to peripheral tissues via LDL receptor (LDLR)
- LDLR expression is regulated by intracellular cholesterol and PCSK9 (which degrades LDLR)
Reverse Cholesterol Transport
- HDL (ApoA-I) picks up excess cholesterol from peripheral tissues
- LCAT esterifies cholesterol → HDL matures
- Cholesterol transferred back to liver via SR-B1 receptor or exchanged to LDL/VLDL via CETP
Atherogenesis — Step by Step
Step 1 — LDL Entry
- LDL particles (especially small, dense LDL) cross endothelium into subendothelial space (intima)
- Entry is driven by particle number (ApoB) and endothelial dysfunction (HTN, smoking, hyperglycemia, shear stress)
Step 2 — Oxidative Modification
- LDL trapped in intima is oxidized → oxidized LDL (ox-LDL)
- ox-LDL activates endothelial cells → expression of ICAM-1, VCAM-1, MCP-1
- Monocytes recruited from blood → enter intima → differentiate into macrophages
Step 3 — Foam Cell Formation
- Macrophages express scavenger receptors (SR-A, CD36) — these are not downregulated by intracellular cholesterol
- Macrophages engulf ox-LDL uncontrolled → become foam cells
- Foam cells accumulate → fatty streak (earliest visible atherosclerotic lesion, present even in children)
Step 4 — Plaque Development
- Smooth muscle cells (SMC) migrate from media → intima → secrete collagen → form fibrous cap
- Necrotic core develops: foam cells die → release cholesterol crystals, proteases, cytokines
- Vulnerable plaque = large necrotic core + thin fibrous cap + active inflammation
Step 5 — Plaque Rupture → ASCVD Event
- Metalloproteinases (MMPs) degrade fibrous cap → plaque rupture
- Subendothelial collagen exposed → platelet aggregation + thrombus formation
- Results: ACS (STEMI/NSTEMI), ischemic stroke, TIA, PAD
Role of Key Lipid Particles in Atherogenesis
LDL-C
- Each LDL particle carries one ApoB → more particles = more intimal entry
- Causal relationship confirmed by Mendelian randomization studies
- Every 1 mmol/L (38.7 mg/dL) reduction in LDL-C → ~22% reduction in MACE
VLDL / Remnant Particles
- AHA 2026 highlights triglyceride-rich remnant particles as independent atherogenic particles
- Remnants are small enough to penetrate endothelium
- Non-HDL-C includes all atherogenic particles (LDL + VLDL + IDL + Lp(a))
- Non-HDL-C = Total cholesterol − HDL-C
Lp(a)
- Lp(a) = LDL + apo(a) linked by disulfide bond
- Pro-atherogenic: enters intima like LDL; promotes foam cell formation
- Pro-thrombotic: apo(a) inhibits fibrinolysis (structural homology with plasminogen)
- Independently increases risk of MI, stroke, aortic stenosis, PAD
- Levels are >90% genetically determined — not modifiable by diet
HDL
- Reverse cholesterol transport: removes cholesterol from vessel wall → liver
- Also has anti-inflammatory, antioxidant, antithrombotic properties
- Low HDL-C (<40 mg/dL men, <50 mg/dL women) = independent CV risk factor
- HDL raising drugs (niacin, CETP inhibitors) have not reduced CV events in trials → HDL function more important than level
PCSK9 — Mechanism Critical for Treatment
- PCSK9 = proprotein convertase subtilisin/kexin type 9
- Synthesized in liver → binds LDLR → targets it for lysosomal degradation
- Loss-of-function PCSK9 mutations → very low LDL-C + protection from ASCVD
- Gain-of-function mutations → very high LDL-C (familial hypercholesterolemia phenotype)
- PCSK9 inhibitors (evolocumab, alirocumab) block this → more LDLR on hepatocyte surface → ↓LDL-C 50–65%
PART 4 — CLINICAL FEATURES
Most Patients Are Asymptomatic
The majority of patients with dyslipidemia have no symptoms until an ASCVD event occurs. Clinical features are therefore divided into:
- Physical signs of lipid deposition
- Manifestations of ASCVD complications
Physical Signs of Lipid Deposition
Xanthomas
Deposits of lipid-laden macrophages in soft tissue:
| Type | Location | Associated Condition |
|---|---|---|
| Tendinous xanthoma | Achilles tendon, extensor tendons of hands | Familial hypercholesterolemia (FH) |
| Tuberous / Tuberoeruptive xanthoma | Elbows, knees | FH, dysbetalipoproteinemia |
| Eruptive xanthoma | Buttocks, shoulders, extensor surfaces | Severe hypertriglyceridemia (TG >1000) |
| Xanthelasma | Medial eyelids (yellowish plaques) | Hypercholesterolemia (not specific) |
| Palmar / Planar xanthoma | Palm creases | Type III dyslipidemia (ApoE2/E2) |
Corneal Arcus (Arcus Senilis)
- White/grey ring around corneal periphery
- Normal in elderly >60 years
- In patients <45 years = suggests significant hypercholesterolemia / FH
Lipemia Retinalis
- Cream-colored retinal vessels on fundoscopy
- Occurs with TG >2000 mg/dL
- Indicates severe hypertriglyceridemia
Hepatosplenomegaly
- Seen in severe hypertriglyceridemia
- Organ enlargement from lipid-laden reticuloendothelial cells
ASCVD Manifestations (Complications)
Coronary Artery Disease (CAD)
- Stable angina: exertional chest tightness, pressure, radiation to arm/jaw
- Acute coronary syndrome (ACS): rest pain, diaphoresis, dyspnea, nausea
- Silent MI: especially in diabetics
Cerebrovascular Disease
- Transient ischemic attack (TIA): transient focal neuro deficits
- Ischemic stroke: sudden weakness, speech difficulty, vision loss
- Carotid bruits on auscultation
Peripheral Arterial Disease (PAD)
- Intermittent claudication: calf pain on walking, relieved by rest
- Rest pain, non-healing ulcers, gangrene (severe)
- Absent peripheral pulses, decreased ankle-brachial index (ABI)
Acute Pancreatitis (Hypertriglyceridemia Specific)
- Severe abdominal pain, nausea, vomiting
- Occurs when TG ≥500 mg/dL (risk rises sharply at ≥1000 mg/dL)
- Eruptive xanthomas may precede pancreatitis
Symptoms by Lipid Type Summary
| Lipid Abnormality | Clinical Feature |
|---|---|
| Elevated LDL-C | Usually asymptomatic; tendon xanthomas, arcus (in FH) |
| Severe hypertriglyceridemia | Eruptive xanthomas, acute pancreatitis, lipemia retinalis |
| Low HDL-C | Asymptomatic; accelerated ASCVD |
| Elevated Lp(a) | Asymptomatic; early ASCVD, aortic stenosis |
| Type III dyslipidemia | Palmar xanthomas, tuberous xanthomas, premature CAD/PAD |
PART 5 — LABORATORY INVESTIGATIONS
Standard Lipid Panel
Obtain fasting lipid panel (9-12 hours fasting preferred) OR non-fasting if hypertriglyceridemia not suspected:
| Test | Normal Value | Significance |
|---|---|---|
| Total Cholesterol (TC) | <200 mg/dL | Screening; less useful than fractions |
| LDL-C | <100 mg/dL (general) | PRIMARY treatment target (AHA 2026) |
| HDL-C | ≥40 mg/dL (men), ≥50 mg/dL (women) | Protective; low = risk factor |
| Triglycerides (TG) | <150 mg/dL | Elevated → remnant particles, pancreatitis risk |
| Non-HDL-C | <130 mg/dL (general) | = TC − HDL-C; includes all atherogenic particles |
| TC/HDL-C ratio | <5 | Risk assessment tool |
AHA 2026: Non-fasting lipid testing is adequate for most clinical scenarios. Fasting is required if TG >400 mg/dL or for accurate LDL-C calculation (Friedewald equation requires fasting).
LDL-C Calculation
Friedewald Equation (valid when TG <400 mg/dL):
LDL-C = Total Cholesterol − HDL-C − (TG ÷ 5)
Martin-Hopkins Equation: More accurate (especially at low LDL-C or high TG) — direct LDL-C measurement preferred when TG ≥400 mg/dL.
Extended Lipid Testing — AHA 2026 Additions
Lipoprotein(a) — Lp(a)
- AHA 2026: Class I — Measure at least once in all adults
- Units: mg/dL or nmol/L (nmol/L preferred — avoids particle size variation)
- Risk thresholds:
- ≥75 nmol/L (≈30 mg/dL) = risk modifier
- ≥125 nmol/L (≈50 mg/dL) = high risk — reclassify upward
- Cannot be meaningfully reduced by lifestyle — genetic determination
- Repeat only if clinical decision-making requires
Apolipoprotein B (ApoB)
- AHA 2026: Selective use to improve risk assessment and guide treatment
- One ApoB per atherogenic particle → better reflects particle burden than LDL-C
- Especially useful when:
- LDL-C and non-HDL-C are discordant
- Hypertriglyceridemia (LDL-C underestimated)
- Metabolic syndrome / diabetes (small dense LDL)
- Treatment goals (AHA 2026):
| Risk Category | ApoB Goal |
|---|---|
| Very high risk | < 65 mg/dL |
| High risk | < 80 mg/dL |
| Primary prevention | < 90 mg/dL |
Additional Investigations for Risk Assessment
| Test | Purpose |
|---|---|
| Fasting glucose / HbA1c | Diabetes screening; input for PREVENT equations |
| eGFR / Creatinine | CKD assessment; input for PREVENT; affects drug dosing |
| Urine albumin-to-creatinine ratio (uACR) | CKD staging; PREVENT risk variable |
| Thyroid function (TSH) | Secondary dyslipidemia (hypothyroidism → ↑LDL-C) |
| Liver function tests (LFTs) | Baseline before statin; secondary dyslipidemia (cholestasis) |
| CK (Creatine Kinase) | Baseline before statin; check if myalgia develops |
| Blood pressure | Major CV risk factor; input for risk equations |
| Fasting insulin / HOMA-IR | Insulin resistance assessment |
| hsCRP | Residual inflammatory risk (e.g., JUPITER trial) |
Coronary Artery Calcium (CAC) Scoring
AHA 2026 gives expanded role to CAC in primary prevention:
| CAC Score | Interpretation | Clinical Action |
|---|---|---|
| 0 | Very low near-term risk | Defer pharmacotherapy; lifestyle + reassess in 5-7 years |
| 1–99 AU | Mild subclinical disease | LDL-C goal <100 mg/dL |
| 100–999 AU or ≥75th %ile | Moderate-high subclinical | LDL-C goal <70 mg/dL |
| ≥ 1000 AU | Severe subclinical disease | LDL-C goal <55 mg/dL |
CAC = 0 in a patient age ≥40 has very high negative predictive value for near-term ASCVD — can safely defer statin therapy with lifestyle only. Incidental CAC found on non-cardiac CT should also trigger lipid-lowering therapy consideration.
Risk Calculation — PREVENT-ASCVD
AHA 2026 replaces the Pooled Cohort Equations with the PREVENT-ASCVD equations:
Variables included:
- Age, sex, race
- Systolic BP (treated vs untreated)
- Total cholesterol, HDL-C
- Diabetes (yes/no) + HbA1c
- Smoking status
- eGFR + uACR (renal function — NEW)
- Zip code-level social deprivation index (NEW)
Outputs:
- 10-year ASCVD risk
- 30-year ASCVD risk (new — enables earlier intervention discussion)
PART 6 — DIAGNOSTIC CRITERIA & CLASSIFICATION
AHA 2026 Classification of Dyslipidemia
By Lipid Parameter
| Disorder | Diagnostic Criterion |
|---|---|
| Hypercholesterolemia | LDL-C ≥130 mg/dL OR total cholesterol ≥200 mg/dL |
| Severe hypercholesterolemia | LDL-C ≥190 mg/dL |
| Low HDL-C | <40 mg/dL (men), <50 mg/dL (women) |
| Borderline high TG | 150–199 mg/dL |
| High TG | 200–499 mg/dL |
| Very high TG | ≥500 mg/dL (pancreatitis risk) |
| Severe hypertriglyceridemia | ≥1000 mg/dL |
| Elevated Lp(a) | ≥75 nmol/L (risk modifier); ≥125 nmol/L (high risk) |
| Elevated non-HDL-C | ≥130 mg/dL |
| Elevated ApoB | ≥90 mg/dL |
Fredrickson / WHO Classification (Phenotypic)
| Type | Elevated Particle | Lipid Pattern | Common Cause |
|---|---|---|---|
| Type I | Chylomicrons | ↑↑↑ TG, TG >1000 | LPL deficiency (rare genetic) |
| Type IIa | LDL | ↑ LDL-C, normal TG | Familial hypercholesterolemia |
| Type IIb | LDL + VLDL | ↑ LDL-C + ↑ TG | Combined hyperlipidemia |
| Type III | IDL / Remnants | ↑ TC + ↑ TG equally | Dysbetalipoproteinemia (ApoE2) |
| Type IV | VLDL | ↑ TG, normal/↑ LDL | Familial hypertriglyceridemia |
| Type V | VLDL + Chylomicrons | ↑↑↑ TG | Combined genetic + secondary |
Primary vs Secondary Dyslipidemia
Primary (Genetic) Causes
| Condition | Mutation | LDL-C Level | Features |
|---|---|---|---|
| Heterozygous FH (HeFH) | LDLR, ApoB, PCSK9 (one allele) | 190–400 mg/dL | Premature CAD, tendon xanthomas |
| Homozygous FH (HoFH) | LDLR (both alleles) | >400–600 mg/dL | CAD in childhood, aortic stenosis |
| Familial combined hyperlipidemia (FCH) | Multiple genes | ↑ LDL-C + ↑ TG | Most common genetic dyslipidemia |
| Familial dysbetalipoproteinemia (Type III) | ApoE2/E2 | ↑ TC + ↑ TG | Palmar xanthomas |
| Familial hypertriglyceridemia | LPL, APOC2 | ↑↑ TG | Pancreatitis risk |
| Elevated Lp(a) | LPA gene | Normal LDL-C | Independent ASCVD risk |
Secondary Causes
| Cause | Lipid Effect |
|---|---|
| Hypothyroidism | ↑ LDL-C, ↑ TG |
| Type 2 Diabetes / Insulin resistance | ↑ TG, ↓ HDL-C, small dense LDL |
| Obesity | ↑ TG, ↓ HDL-C |
| Nephrotic syndrome | ↑ LDL-C, ↑ TG |
| Chronic kidney disease | ↑ TG, ↓ HDL-C |
| Cholestatic liver disease | ↑ TC, ↑ LDL-C |
| Cushing syndrome | ↑ LDL-C, ↑ TG |
| Alcohol excess | ↑↑ TG, ↑ HDL-C |
| Thiazide diuretics | ↑ LDL-C, ↑ TG |
| Beta-blockers | ↑ TG, ↓ HDL-C |
| Corticosteroids | ↑ LDL-C, ↑ TG |
| Cyclosporin / Tacrolimus | ↑ LDL-C |
| HIV antiretrovirals (some) | ↑ TG, ↑ LDL-C |
Familial Hypercholesterolemia — Diagnostic Criteria
Dutch Lipid Clinic Network (DLCN) Score (used clinically with AHA 2026):
| Criterion | Points |
|---|---|
| Family Hx: premature ASCVD (1st degree, <55M / <60F) | 1 |
| Family Hx: known FH in 1st degree relative | 2 |
| Personal Hx: premature ASCVD (<55M / <60F) | 2 |
| Tendon xanthomas (patient or 1st degree relative) | 6 |
| Corneal arcus age <45 | 4 |
| LDL-C ≥330 mg/dL | 8 |
| LDL-C 250–329 mg/dL | 5 |
| LDL-C 190–249 mg/dL | 3 |
| LDL-C 155–189 mg/dL | 1 |
| Causative mutation confirmed | 8 |
| Score | Diagnosis |
|---|---|
| >8 | Definite FH |
| 6–8 | Probable FH |
| 3–5 | Possible FH |
| <3 | Unlikely FH |
PART 7 — RISK FACTORS
Non-Modifiable Risk Factors
| Risk Factor | Detail |
|---|---|
| Age | Men ≥45 years; Women ≥55 years (post-menopause) |
| Sex | Men have earlier ASCVD onset; women catch up after menopause |
| Genetics / Family History | FH, elevated Lp(a), familial combined hyperlipidemia |
| Ethnicity | South Asian → higher Lp(a) + TG, lower HDL; Black Americans → higher Lp(a) |
Modifiable Risk Factors
Lifestyle
| Risk Factor | Mechanism |
|---|---|
| Unhealthy diet | Saturated fat → ↑ LDL-C; trans fats → ↑ LDL-C + ↓ HDL-C; fructose → ↑ TG |
| Physical inactivity | ↓ LPL activity → ↑ TG; ↓ HDL-C |
| Obesity (especially central) | ↑ VLDL secretion → ↑ TG; ↓ HDL-C; insulin resistance |
| Alcohol excess | ↑ hepatic VLDL → ↑↑ TG |
| Smoking | Oxidizes LDL; ↓ HDL-C; endothelial dysfunction |
Medical Comorbidities
| Condition | Lipid Effect |
|---|---|
| Type 2 Diabetes | ↑ TG, ↓ HDL-C, small dense LDL (most atherogenic form) |
| Hypertension | Synergistic ASCVD risk with dyslipidemia |
| Metabolic Syndrome | Combination of ↑ TG + ↓ HDL + central obesity + ↑ BP + ↑ glucose |
| CKD | ↓ urate excretion; altered lipoprotein metabolism |
| Hypothyroidism | ↑ LDL-C via ↓ LDLR expression |
Drug-Induced Dyslipidemia
| Drug | Effect |
|---|---|
| Thiazide diuretics | ↑ LDL-C, ↑ TG |
| Beta-blockers (non-cardioselective) | ↑ TG, ↓ HDL-C |
| Corticosteroids | ↑ LDL-C, ↑ TG |
| Cyclosporin | ↑ LDL-C (↓ LDLR expression) |
| Isotretinoin | ↑ TG, ↑ LDL-C |
| HIV protease inhibitors | ↑ TG, ↑ LDL-C |
| Estrogens (oral) | ↑ TG |
| Progestins | ↓ HDL-C |
Risk Enhancers (AHA 2026 — Reclassify Risk Upward)
When PREVENT-ASCVD risk estimate is borderline, these factors push treatment decisions:
- LDL-C ≥160 mg/dL (primary prevention)
- Lp(a) ≥125 nmol/L
- ApoB ≥130 mg/dL
- hsCRP ≥2.0 mg/L
- ABI <0.9 (PAD)
- Chronic inflammatory conditions (RA, psoriasis, SLE)
- HIV infection
- Premature menopause (<40 years)
- Preeclampsia history
- South Asian ancestry
- Social deprivation / low SES
PART 8 — TREATMENT & MANAGEMENT
AHA 2026 Treatment Framework
The framework is built on three levels of prevention:
| Level | Target Population |
|---|---|
| Primordial prevention | Healthy individuals — prevent development of risk factors |
| Primary prevention | Individuals with risk factors but no established ASCVD |
| Secondary prevention | Individuals with established ASCVD |
AHA 2026 LDL-C Treatment Goals
| Risk Category | LDL-C Goal | Non-HDL-C Goal | ApoB Goal |
|---|---|---|---|
| Secondary prevention — Very High Risk | < 55 mg/dL | < 85 mg/dL | < 65 mg/dL |
| Secondary prevention — Not Very High Risk | < 70 mg/dL | < 100 mg/dL | < 80 mg/dL |
| Primary prev — High risk (PREVENT ≥20%) | < 70 mg/dL | < 100 mg/dL | < 80 mg/dL |
| Primary prev — Intermediate risk (7.5–20%) | < 100 mg/dL | < 130 mg/dL | < 90 mg/dL |
| Primary prev — Borderline risk (5–7.5%) | Lifestyle ± statin | — | — |
| Subclinical — CAC ≥100 or ≥75th %ile | < 70 mg/dL | < 100 mg/dL | — |
| Subclinical — CAC ≥1000 | < 55 mg/dL | < 85 mg/dL | — |
| Diabetes (no ASCVD, high risk) | < 70 mg/dL | < 100 mg/dL | — |
| Familial Hypercholesterolemia | ≥50% reduction from baseline | — | — |
In ALL patients on pharmacotherapy: Also target ≥50% LDL-C reduction from pre-treatment baseline.
Very High Risk = ≥2 major ASCVD events OR 1 major ASCVD event + ≥2 high-risk conditions (diabetes, CKD, heart failure, PAD, HTN, active smoking, age >65, prior PCI/CABG)
A. NON-PHARMACOLOGICAL MANAGEMENT
1. Dietary Modifications
Dietary Pattern
| Recommendation | Evidence | LDL-C Effect |
|---|---|---|
| Mediterranean diet | Strong | ↓ LDL-C 5-10%, ↓ ASCVD events 30% (PREDIMED) |
| DASH diet | Strong | ↓ LDL-C, ↓ BP |
| Plant-based / Portfolio diet | Moderate-strong | ↓ LDL-C up to 30% |
| Reduce saturated fat <7% of total calories | Strong | ↓ LDL-C ~5-8% per 1% reduction in sat fat |
| Eliminate trans fats completely | Strong | ↓ LDL-C + ↑ HDL-C |
| Increase soluble fiber 10-25 g/day | Moderate | ↓ LDL-C ~5% |
| Plant sterols 2 g/day | Strong | ↓ LDL-C ~8-10% |
| Reduce dietary cholesterol <200 mg/day | Moderate | ↓ LDL-C modestly |
Foods to Reduce / Avoid
- Red meat, processed meat, organ meats
- Full-fat dairy (butter, cheese, cream)
- Tropical oils (coconut oil, palm oil)
- Fried foods, fast food, pastries
- Sugar-sweetened beverages, fructose (↑ TG)
- Excess alcohol (especially for hypertriglyceridemia)
Foods to Increase
- Oily fish (salmon, mackerel, sardines) — omega-3
- Nuts (walnuts, almonds)
- Legumes, whole grains
- Fruits and vegetables (soluble fiber)
- Soy protein
- Low-fat dairy (mildly lowers LDL-C)
- Coffee (filtered — not unfiltered which raises LDL-C)
Dietary Supplements — AHA 2026 Position
Class 3 (No Benefit): Fish oil, red yeast rice, plant sterols are NOT recommended as routine ASCVD risk-reduction strategies. Evidence is limited and inconsistent.
2. Physical Activity
| Recommendation | Specifics |
|---|---|
| Aerobic exercise | ≥150 min/week moderate-intensity OR ≥75 min/week vigorous |
| Resistance training | ≥2 sessions/week |
| Reduce sedentary time | Break up prolonged sitting every 30 minutes |
| Effects on lipids | ↓ TG 20-30%; ↑ HDL-C 5-10%; modest ↓ LDL-C |
3. Weight Management
| Weight Loss | Lipid Effect |
|---|---|
| 5-10% body weight loss | ↓ LDL-C 5-8 mg/dL, ↓ TG 15-20%, ↑ HDL-C |
| >10% weight loss | More significant TG reduction |
| Bariatric surgery | ↓ LDL-C 30%, ↓ TG 50%, ↑ HDL-C 15% |
| GLP-1 agonists (semaglutide) | Weight loss + modest ↓ LDL-C, ↓ TG; ↓ ASCVD events (SUSTAIN-6, LEADER) |
4. Smoking Cessation
- Smoking cessation → ↑ HDL-C 4-8 mg/dL within months
- Reduces oxidative stress → less ox-LDL formation
- Endothelial function improves within weeks
- Significant reduction in ASCVD risk
5. Alcohol Reduction
- Limiting alcohol reduces hypertriglyceridemia significantly
- For TG ≥500 mg/dL → abstinence from alcohol is mandatory
- No protective "safe" alcohol level for ASCVD in AHA 2026
B. PHARMACOLOGICAL MANAGEMENT
Drug Class 1 — Statins (HMG-CoA Reductase Inhibitors)
First-line in all risk categories requiring pharmacotherapy
Mechanism:
- Inhibit HMG-CoA reductase → ↓ intracellular cholesterol synthesis
- ↑ LDLR expression on hepatocytes → ↑ LDL clearance from plasma
- Pleiotropic effects: anti-inflammatory, plaque-stabilizing, endothelial-protective
Statin Intensity Classification (AHA 2026):
| Intensity | Agents | LDL-C Reduction |
|---|---|---|
| High | Rosuvastatin 20–40 mg; Atorvastatin 40–80 mg | ≥50% |
| Moderate | Rosuvastatin 5–10 mg; Atorvastatin 10–20 mg; Simvastatin 20–40 mg; Pravastatin 40–80 mg | 30–49% |
| Low | Simvastatin 10 mg; Pravastatin 10–20 mg; Fluvastatin 20–40 mg | <30% |
AHA 2026 Statin Recommendations:
- Very high risk → High-intensity statin (mandatory first step)
- Secondary prevention → high-intensity statin regardless of baseline LDL-C
- Primary prevention PREVENT ≥7.5% + risk enhancers → moderate-to-high intensity statin
- Diabetes (any) → statin therapy recommended
Side Effects:
| Effect | Frequency | Management |
|---|---|---|
| Myalgia (muscle pain without CK rise) | 5–10% | Dose reduction, switch statin |
| Myopathy (CK >10× ULN) | 0.1% | Stop statin immediately |
| Rhabdomyolysis | <0.01% | Stop statin, IV hydration |
| New-onset diabetes | ~10–12% extra risk | Benefits still outweigh risk |
| LFT elevation (>3× ULN) | <1% | Usually transient; recheck |
| HLA-B*5801 (Asian patients) | — | Allopurinol but also relevant context |
Statin benefit ALWAYS outweighs risk in high-risk patients. Do not discontinue without specialist review.
Drug Class 2 — Ezetimibe
Add-on to statin when LDL-C goal not met
- Mechanism: Inhibits NPC1L1 transporter in intestinal brush border → ↓ cholesterol absorption
- LDL-C reduction: 18–24% (additional, on top of statin)
- Dose: 10 mg/day
- Key trial: IMPROVE-IT (simvastatin + ezetimibe vs simvastatin alone → ↓ MACE 6.4%)
- AHA 2026: Add ezetimibe if LDL-C goal not achieved on maximally tolerated statin
- Side effects: Generally well tolerated; mild GI upset, rare myopathy
Drug Class 3 — PCSK9 Inhibitors (Monoclonal Antibodies)
For very high / high risk not at LDL-C goal on statin + ezetimibe
| Drug | Dose | Frequency |
|---|---|---|
| Evolocumab (Repatha) | 140 mg SC | Every 2 weeks |
| Alirocumab (Praluent) | 75–150 mg SC | Every 2 weeks |
- Mechanism: Monoclonal antibody binds PCSK9 → prevents LDLR degradation → more LDLR → ↓ LDL-C 50–65%
- Key trials: FOURIER (evolocumab, ↓ MACE 15%), ODYSSEY OUTCOMES (alirocumab, ↓ MACE 15%)
- Also reduces Lp(a) by ~20–25%
- AHA 2026: For very high risk not at LDL-C goal; no longer strictly sequential — choose based on LDL-C gap needed
- Side effects: Injection site reactions; generally very well tolerated; safety data to LDL-C as low as 30 mg/dL with no safety concerns
Drug Class 4 — Bempedoic Acid
For statin-intolerant patients
- Mechanism: Inhibits ATP-citrate lyase (ACL) — upstream of HMG-CoA reductase; activated only in liver (not muscle → less myopathy)
- LDL-C reduction: ~18% (alone); ~28% with ezetimibe (combination tablet available)
- Dose: 180 mg/day oral
- Key trial: CLEAR Outcomes (2023) — bempedoic acid in statin-intolerant patients → ↓ MACE 13%
- AHA 2026: Recommended for statin-intolerant patients requiring LDL-C lowering
- Side effects: Gout (↑ uric acid — avoid in active gout), tendon rupture (rare), GI upset
Drug Class 5 — Inclisiran (siRNA PCSK9 Inhibitor)
Novel RNA interference therapy
- Mechanism: Small interfering RNA (siRNA) → silences PCSK9 mRNA in hepatocytes → ↓ PCSK9 production → ↑ LDLR → ↓ LDL-C ~50%
- Dose: 284 mg SC at 0, 3 months, then every 6 months
- Advantage over mAbs: Less frequent dosing → better adherence
- Key trials: ORION-10, ORION-11 → consistent ~50% LDL-C reduction
- AHA 2026: Second-line if PCSK9 mAb not tolerated or accessible
- Side effects: Injection site reactions; generally well tolerated
Drug Class 6 — Fibrates
For hypertriglyceridemia
- Mechanism: PPAR-α agonists → ↑ LPL activity → ↓ VLDL → ↓ TG; ↑ HDL-C
- TG reduction: 30–50%; HDL-C: ↑10–20%; LDL-C: variable
- Agents: Fenofibrate, gemfibrozil, bezafibrate
- Indication: TG ≥500 mg/dL (pancreatitis prevention); adjunct for combined dyslipidemia
- Caution: Gemfibrozil + statin → ↑ myopathy risk (pharmacokinetic interaction) — prefer fenofibrate with statins
- AHA 2026: Not recommended for primary ASCVD risk reduction alone; used for TG management
Drug Class 7 — Omega-3 Fatty Acids (EPA)
For hypertriglyceridemia — only EPA with proven ASCVD benefit
| Drug | Active Component | Evidence |
|---|---|---|
| Icosapentaenoic acid (IPE) (Vascepa) | Pure EPA 4 g/day | REDUCE-IT: ↓ MACE 25% in statin-treated patients with TG ≥150 |
| Mixed EPA+DHA (Lovaza) | EPA + DHA | Reduces TG but no CV benefit in STRENGTH trial |
AHA 2026: Icosapentaenoic acid (EPA only) 4 g/day recommended for ASCVD risk reduction in patients on statin with TG 135–499 mg/dL. Mixed EPA+DHA formulations do NOT have the same benefit.
Drug Class 8 — Evinacumab (for Homozygous FH only)
- Mechanism: Monoclonal antibody against ANGPTL3 → ↑ LPL + EL activity → ↓ LDL-C even in LDLR-null patients
- LDL-C reduction: ~47% in HoFH (LDL-C independent of LDLR expression — works even when no functional receptors)
- AHA 2026: Approved add-on for HoFH patients not at goal despite max therapy
- Dose: 15 mg/kg IV every 4 weeks
Drug Class 9 — Pelacarsen (Lp(a) Targeting — Pipeline)
- Mechanism: Antisense oligonucleotide → inhibits hepatic apo(a) synthesis → ↓ Lp(a) by ~80%
- Status: Phase 3 LPA-HPIV trial (Lp(a) HORIZON trial) results anticipated — AHA 2026 acknowledges as emerging therapy
- AHA 2026: Not yet a guideline-endorsed treatment target for Lp(a) — but notes Lp(a) will likely become a pharmacological target in near future
Treatment Algorithm Summary
ESTABLISH RISK CATEGORY (using PREVENT-ASCVD equations + CAC if needed)
↓
ALL PATIENTS → LIFESTYLE MODIFICATIONS (diet, exercise, weight, smoking)
↓
If pharmacotherapy indicated:
↓
STEP 1 → High-intensity statin (rosuvastatin 20-40 mg OR atorvastatin 40-80 mg)
Target: ≥50% LDL-C reduction
↓
Recheck lipid panel in 4-12 weeks
↓
STEP 2 → If LDL-C goal not met: ADD EZETIMIBE 10 mg/day
↓
Recheck lipid panel in 4-12 weeks
↓
STEP 3 → If LDL-C goal still not met (very/high risk):
ADD PCSK9 INHIBITOR (evolocumab or alirocumab)
[AHA 2026: No longer mandatory to wait — can add earlier based on LDL-C gap]
↓
IF STATIN INTOLERANT → Replace statin with:
Bempedoic acid ± ezetimibe
OR inclisiran
OR PCSK9 inhibitor alone
↓
SPECIAL:
- HoFH → Add evinacumab + consider LDL apheresis
- TG ≥500 → Fibrate first; EPA (4g/day) if TG 135-499 on statin
- Elevated Lp(a) → PCSK9 inhibitor (↓ 20-25%); pelacarsen (investigational)
Monitoring After Therapy
| Timepoint | Action |
|---|---|
| Baseline | Lipid panel, LFTs, CK, fasting glucose, HbA1c, eGFR, Lp(a) |
| 4-12 weeks after starting/changing therapy | Repeat fasting lipid panel; assess % reduction; check adherence |
| Every 6-12 months once at goal | Ongoing monitoring; assess tolerability; reinforce lifestyle |
| Annually | Reassess CV risk; update PREVENT score; intensify if goals not met |
Both AHA 2026 guidelines identify therapeutic inertia (failure to intensify treatment despite uncontrolled lipids) as a major barrier to achieving LDL-C goals.
Special Population Management Summary
| Population | Key Management Points |
|---|---|
| Diabetes (T2DM) | High-intensity statin regardless of LDL-C; LDL-C goal <70 (high) or <55 (very high risk) |
| Heterozygous FH | High-intensity statin + ezetimibe; add PCSK9i if not at goal; cascade screen family |
| Homozygous FH | Max statin + ezetimibe + PCSK9i + evinacumab ± LDL apheresis |
| CKD (non-dialysis) | Statin ± ezetimibe; avoid high-dose statins in severe CKD; dose-adjust |
| Elderly ≥75 years | Secondary prevention: continue statin; primary prevention: individualize |
| Children (FH) | Statin from age 8-10 in HeFH if LDL-C >190 mg/dL despite lifestyle |
| Hypertriglyceridemia | Lifestyle first; EPA 4 g/day if TG 135-499 on statin; fibrate if TG ≥500 |
| Post-ACS | High-intensity statin before discharge; add ezetimibe early; PCSK9i at discharge if VHR |
SUMMARY TABLE — AHA 2026 Key Numbers
| Parameter | Value |
|---|---|
| Very high risk LDL-C goal | < 55 mg/dL |
| High risk / secondary prevention LDL-C goal | < 70 mg/dL |
| Primary prevention intermediate risk goal | < 100 mg/dL |
| Minimum LDL-C reduction on therapy | ≥ 50% |
| Lp(a) screening | Once in all adults (Class I) |
| CAC = 0 | Defer pharmacotherapy |
| Recheck lipids after new therapy | 4–12 weeks |
| High-intensity statin | Rosuvastatin 20–40 mg / Atorvastatin 40–80 mg |
| Dietary supplements for LDL-C | Class 3 — NOT recommended |
| PCSK9 inhibitor strategy | No longer strictly sequential |
References: Blumenthal RS, Morris PB et al. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. March 2026. JACC Guideline-at-a-Glance. Volume 87, Number 19. 2026.
This is the complete structured topic presentation based on AHA 2026. Let me know if you need any section expanded, simplified, or formatted as slides or a document.
Give me short and crisp for topic presentation not long with all info
DYSLIPIDEMIA
AHA / ACC 2026 Guidelines — Topic Presentation
1. INTRODUCTION
- Dyslipidemia = abnormal levels of lipoproteins (↑LDL, ↑TG, ↓HDL, ↑Lp(a))
- Leading modifiable risk factor for ASCVD
- AHA 2026 replaces 2018 guideline — broader scope beyond LDL-C alone
- Key shift: from treating a number → treating lifetime cardiovascular risk
2. EPIDEMIOLOGY
- CVD = #1 cause of death globally (~18 million deaths/year)
- ~94 million U.S. adults have TC ≥200 mg/dL
- ~28% have LDL-C ≥130 mg/dL
- ~20% have elevated Lp(a) ≥50 mg/dL
- Only 55% of very-high-risk patients reach LDL-C goals
- FH affects 1 in 250 — >90% undiagnosed
3. PATHOPHYSIOLOGY
↑ LDL-C (ApoB)
↓
Enters subendothelial space
↓
Oxidized → LDL (ox-LDL)
↓
Macrophage engulfs → Foam cells → Fatty streak
↓
Fibrous cap + Necrotic core → Plaque
↓
Rupture → Thrombus → ACS / Stroke / PAD
Key particles:
- LDL-C — primary atherogenic driver
- Remnant particles — now highlighted in AHA 2026
- Lp(a) — pro-atherogenic + pro-thrombotic; genetic
- ApoB — one per atherogenic particle; best reflects particle burden
4. CLINICAL FEATURES
Usually asymptomatic until ASCVD event occurs
| Sign | Condition |
|---|---|
| Tendon xanthomas | Familial hypercholesterolemia |
| Xanthelasma | Hypercholesterolemia |
| Corneal arcus <45 yrs | Significant hypercholesterolemia |
| Eruptive xanthomas | TG >1000 mg/dL |
| Acute pancreatitis | TG ≥500 mg/dL |
| Angina / MI | Established ASCVD |
| Claudication | Peripheral arterial disease |
5. LAB INVESTIGATIONS
Standard lipid panel (fasting or non-fasting):
| Test | Target (General) |
|---|---|
| LDL-C | < 100 mg/dL |
| Non-HDL-C | < 130 mg/dL |
| HDL-C | ≥40 (M) / ≥50 (F) mg/dL |
| Triglycerides | < 150 mg/dL |
AHA 2026 additions:
- Lp(a) — once in all adults (Class I)
- ApoB — selective use; goal <65–90 mg/dL by risk
- CAC score — expands primary prevention decisions
- PREVENT-ASCVD — 10 + 30-year risk (replaces PCE)
- Supporting: HbA1c, eGFR, uACR, hsCRP, LFTs, CK
6. DIAGNOSTIC CRITERIA & CLASSIFICATION
By lipid level:
| Disorder | Value |
|---|---|
| Hypercholesterolemia | LDL-C ≥130 mg/dL |
| Severe hypercholesterolemia | LDL-C ≥190 mg/dL (consider FH) |
| Hypertriglyceridemia | TG ≥150 mg/dL |
| Very high TG | TG ≥500 mg/dL |
| Elevated Lp(a) | ≥125 nmol/L (high risk) |
Primary vs Secondary:
- Primary — genetic: FH, familial combined hyperlipidemia, elevated Lp(a)
- Secondary — DM, hypothyroidism, CKD, obesity, alcohol, drugs (thiazides, steroids, cyclosporin)
Fredrickson Types (simplified):
| Type | Elevated | Key Feature |
|---|---|---|
| IIa | LDL | FH pattern |
| IIb | LDL + VLDL | Combined |
| IV | VLDL | High TG |
| V | VLDL + Chylomicrons | Pancreatitis risk |
7. RISK FACTORS
Non-modifiable:
- Age (M ≥45 / F ≥55), male sex, family history, genetics, ethnicity
Modifiable:
- Unhealthy diet, physical inactivity, obesity, smoking, alcohol excess
- DM, hypertension, metabolic syndrome, CKD
Drug-induced:
- Thiazides, beta-blockers, corticosteroids, cyclosporin, HIV ART
AHA 2026 Risk Enhancers (reclassify borderline → treat):
- Lp(a) ≥125 nmol/L, hsCRP ≥2 mg/L, ABI <0.9, chronic inflammation (RA, SLE), preeclampsia history, South Asian ancestry, social deprivation
8. TREATMENT & MANAGEMENT
LDL-C Goals (AHA 2026)
| Risk Category | LDL-C Goal |
|---|---|
| Very High Risk (secondary prevention) | < 55 mg/dL |
| Secondary prevention (not VHR) | < 70 mg/dL |
| Primary prevention — high risk | < 70 mg/dL |
| Primary prevention — intermediate | < 100 mg/dL |
| CAC ≥1000 | < 55 mg/dL |
All patients on therapy: also achieve ≥50% LDL-C reduction
A. NON-PHARMACOLOGICAL
| Intervention | Effect on Lipids |
|---|---|
| Mediterranean / DASH diet | ↓ LDL-C 5-10% |
| Reduce saturated fat <7% kcal | ↓ LDL-C 5-8% |
| Soluble fiber 10-25 g/day | ↓ LDL-C ~5% |
| Plant sterols 2 g/day | ↓ LDL-C 8-10% |
| Aerobic exercise ≥150 min/wk | ↓ TG 20-30%, ↑ HDL |
| Weight loss 5-10% | ↓ LDL-C, ↓ TG, ↑ HDL |
| Smoking cessation | ↑ HDL-C 4-8 mg/dL |
| Alcohol reduction | ↓ TG significantly |
❌ AHA 2026 Class 3: Fish oil, red yeast rice, plant sterol supplements — NOT recommended as ASCVD prevention
B. PHARMACOLOGICAL
| Drug | Mechanism | LDL-C ↓ | When to Use |
|---|---|---|---|
| Statin (atorva 40-80 / rosuva 20-40) | ↓ HMG-CoA → ↑ LDLR | 30–55% | First-line — all risk categories |
| Ezetimibe 10 mg | ↓ intestinal absorption (NPC1L1) | +18–24% | Add if goal not met on statin |
| PCSK9 inhibitor (evolocumab / alirocumab) | ↑ LDLR expression | +50–65% | Very high risk not at goal |
| Bempedoic acid 180 mg | ↓ ATP-citrate lyase (liver only) | +18% | Statin-intolerant (CLEAR Outcomes) |
| Inclisiran (siRNA) | Silences PCSK9 mRNA | +50% | Alt to PCSK9 mAb; dosing q6 months |
| Fibrates | PPAR-α → ↑ LPL | TG ↓30-50% | TG ≥500 mg/dL (pancreatitis) |
| EPA (Vascepa 4 g) | ↓ TG, anti-inflammatory | TG ↓25% + ↓MACE | TG 135-499 on statin (REDUCE-IT) |
| Evinacumab | Anti-ANGPTL3 | ↓47% | Homozygous FH only |
Treatment Algorithm
ALL PATIENTS
→ Lifestyle modification first
PHARMACOTHERAPY:
STEP 1 → High-intensity statin
STEP 2 → + Ezetimibe (if goal not met)
STEP 3 → + PCSK9 inhibitor (if still not at goal)
STATIN INTOLERANT → Bempedoic acid ± ezetimibe / Inclisiran
SPECIAL:
• TG ≥500 → Fibrate first
• TG 135-499 on statin → EPA 4 g/day
• HoFH → Evinacumab + LDL apheresis
Monitor: Recheck lipids 4–12 weeks after change → then every 6–12 months
KEY NUMBERS TO REMEMBER
| Very high risk goal | LDL-C <55 mg/dL |
| High risk goal | LDL-C <70 mg/dL |
| Reduction target | ≥50% from baseline |
| Lp(a) screening | Once — all adults (Class I) |
| CAC = 0 | Defer statin |
| Recheck after therapy | 4–12 weeks |
| High-intensity statin | Atorva 40–80 / Rosuva 20–40 |
| Dietary supplements | NOT recommended (Class 3) |
Source: AHA/ACC 2026 Guideline on the Management of Dyslipidemia — Circulation, March 2026
This is a shared conversation. Sign in to Orris to start your own chat.